Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
DW

David Erick Wright — 16 Patents

MYMyelos: 7 patents #1 of 6Top 20%
AMAmgen: 6 patents #576 of 2,867Top 25%
MAMcneil Ab: 2 patents #42 of 127Top 35%
Ramona, CA: #45 of 542 inventorsTop 9%
California: #37,952 of 386,348 inventorsTop 10%
Overall (All Time): #284,196 of 4,157,543Top 7%
16 Patents All Time
David Erick Wright has been granted 16 US patents while listed as an inventor at Myelos. The first was granted in 1987 and the most recent in January 2025. David Erick Wright ranks #284,196 of 4,157,543 US inventors in our database (top 6.8%). Patent records list David Erick Wright in Ramona, CA, US.

Issued Patents All Time

Showing 1–16 of 16 patents

Patent #TitleCo-InventorsDateApprox Value ⓘ
12188927 Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy Theresa Rosario-Jansen 2025-01-07
11982670 Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy Theresa Rosario-Jansen 2024-05-14
11639927 Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy Theresa Rosario-Jansen 2023-05-02
11598767 Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy Theresa Rosario-Jansen 2023-03-07
10823727 Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy Theresa Rosario-Jansen 2020-11-03
10139399 Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy Theresa Rosario-Jansen 2018-11-27
9377454 Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy Theresa Rosario-Jansen 2016-06-28
8063016 Retro-inverso peptides derived from interleukin-6 D. Elliot Parks 2011-11-22
7754688 Methods of using retro-inverso peptides derived from interleukin-6 D. Elliott Parks 2010-07-13
7754690 Method of using retro inverso peptides derived from leukemia inhibitory factor D. Elliott Parks 2010-07-13
7135461 Retro-inverso peptides derived from interleukin-6 D. Elliott Parks 2006-11-14
7115571 Retro-inverso peptides derived from interleukin-3 D. Elliott Parks 2006-10-03
7109168 Retro-inverso peptides derived from leukemia inhibitory factor D. Elliott Parks 2006-09-19
6458357 Retro-inverso neurotrophic and analgesic peptides Michael White, John S. O'Brien 2002-10-01
4742156 Peptide antagonists of neurokinin B and opthalmic solutions containing them 1988-05-03 $11,554,000
4665157 Peptide antagonists of neurokinin B 1987-05-12 $12,895,000